US 7423008B2
· Rohr et al.
· 2008
[cited by applicant]
US 8772253B2
· González et al.
· 2014
[cited by applicant]
US 9447135B2
· Rohr et al.
· 2016
[cited by applicant]
US 20130071482A1
· Bae et al.
· 2013
[cited by applicant]
US 20130101632A1
· Scott et al.
· 2013
[cited by applicant]
EP 2151448
· 2010
[cited by applicant]
EP 2457921
· 2014
[cited by applicant]
WO WO2014093652
· 2014
[cited by applicant]
WO WO2017046403A1
· 2017
[cited by examiner]
WO WO2020106357
· 2020
[cited by applicant]
WO WO2021055489
· 2021
[cited by applicant]
Koibuchi et al. Malignant Rhabdoid Tumor of the Breast: A Case Report, 1995, 25, 273-277 (Year: 1995).
[cited by examiner]
Cecil Textbook of Medicine, 20th Ed, vol. 1, 1997, p. 1004-1010 (Year: 1997).
[cited by examiner]
Wu et al. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021, 2022, 15, 143 (Year: 2022).
[cited by examiner]
Litton JK, Burstein HJ, Turner NC. Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. Jan. 2019;39:e1-e7. doi: 10.1200/EDBK_237715. Epub May 17, 2019. PMID: 31099622. (Year: 2019).
[cited by examiner]
Kalimuthu SN, Chetty R. Gene of the month: SMARCB1. J Clin Pathol. Jun. 2016;69(6):484-9. doi: 10.1136/jclinpath-2016-203650. Epub Mar. 3, 2016. PMID: 26941181; Pmcid: PMC4914571. (Year: 2016).
[cited by examiner]
Mimori K, Inoue H, Shiraishi T, Ueo H, Mafune K, Tanaka Y, Mori M. A single-nucleotide polymorphism of SMARCB1 in human breast cancers. Genomics. Sep. 2002;80(3):254-8. doi: 10.1006/geno.2002.6829. PMID: 12213194. (Year…
[cited by examiner]
Chassse et al., “Abstract 4643: Mithramycin amplifies the imbalance between the BAF and PRC2 complexes to drive apoptosis in rhabdoid tumor”, Cancer Res 78(13_Supplement): 4634, 2018.
[cited by applicant]
Extended European Search Report and Written Opinion for EP Application No. 20865597.7 dated Aug. 7, 2023, 8 pages.
[cited by applicant]
Boulay, G. et al., “Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain.,”
[cited by applicant]
Chasse, M. H. et al., “Abstract 2883: Mithramycin inhibits KDM6A (Utx) and SWI/SNF to induce apoptosis in malignant rhabdoid tumor,”
[cited by applicant]
Chasse, M. H. et al., “SWI/SNF Inhibition Induces Epigenetic Reprogramming and Durable Tumor Regression in Rhabdoid Tumor,” 2019, 1 page.
[cited by applicant]
Chasse, M. H. et al., “Direct therapeutic targeting of SWI/SNF induces epigenetic reprogramming and durable tumor regression in rhabdoid tumor,”
[cited by applicant]
Erkek, S. et al., “Comprehensive analysis of chromatin states in atypical teratoid/rhabdoid tumor identifies diverging roles for SWI/SNF and Polycomb in gene regulation,”
[cited by applicant]
Grohar, P. J. et al., “Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening,”
[cited by applicant]
Harlow, M. L. et al., “Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule dependent Manner,”
[cited by applicant]
Kofman S. et al., “Mithramycin in the Treatment of Metastatic Ewing's Sarcoma,”
[cited by applicant]
Michel, B. C. et al., “A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation,”
[cited by applicant]
Núñez, L. E. et al., “A Novel Mithramycin Analogue with High Antitumor Activity and Less Toxicity Generated by Combinatorial Biosynthesis,”
[cited by applicant]
Osgood, C. L. et al., “Identification of Mithramycin Analogues with Improved Targeting of the EWS-FL11 Transcription Factor,”
[cited by applicant]
PCT International Preliminary Report on Patentability Opinion issued in International Patent Application No. PCT/US2020/051088, dated Mar. 31, 2022.
[cited by applicant]
PCT International Search Report and Written Opinion issued in International Patent Application No. PCT/US2020/051088, dated Feb. 17, 2021.
[cited by applicant]
Selvanathan, S. P. et al., “EWS-FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex,”
[cited by applicant]
Teicher, B. A. et al., “Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression,”
[cited by applicant]
Tornin, J. et al., “Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma,”
[cited by applicant]
Wang, X. et al., “BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors,” Nature Communications, 10 (2019): 1-11.
[cited by applicant]
Wang, X. et al., “Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent upon activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex,”
[cited by applicant]